PharmaCyte Biotech, Inc. (PMCB) · Nov 19, 2026 · Share issuance
Warrant exchange — 851,304 warrants exchanged for 4,982,272 shares; maturity extended to September 2, 2027
PharmaCyte Biotech’s share issuance filing converts part of its Q/C warrant position into common stock, while extending Q/C’s preferred maturity to September 2027.
PharmaCyte is still a non-revenue cancer-biotech company trying to clear a clinical hold on its pancreatic-cancer IND, while curtailing program spending and holding a sizable cash and investment portfolio. The filing is therefore a balance-sheet and portfolio event—not progress on the clinical program.
The Q/C investment becomes more directly monetizable, but not immediately cash. PharmaCyte will exchange 851,304 Q/C long-term warrants for 4,982,272 Q/C common shares. That replaces an option-like asset with common stock, potentially simplifying a future sale, but the shares still require Nasdaq approval and delivery; the agreement does not provide PharmaCyte with cash today. The exchange also covers only the specified warrants, with the remaining warrants continuing to exist.
| Figure | Filing figure | Comparison |
|---|---|---|
| Warrants exchanged (Agreement) | 851,304 | |
| Q/C common shares received (Agreement) | 4,982,272 | |
| Preferred maturity date (Series H Amendment) | September 2, 2027 | March 2, 2027 |
The maturity extension gives Q/C more runway and protects PharmaCyte from an earlier liquidity event. PharmaCyte controls more than a majority of Q/C’s Series H preferred stock and consents to moving the maturity date from March 2, 2027 to September 2, 2027. 〔0〕 That is helpful for the counterparty and may improve the value or survivability of PharmaCyte’s Q/C position, but it also defers a potential repayment or conversion decision by six months.
The filing does not change PharmaCyte’s core operating bottleneck. There is no new financing for PharmaCyte, no FDA clinical-hold removal, no trial restart, and no change to its non-revenue development status. The shares are also not freely saleable immediately: PharmaCyte receives demand registration rights only after 90 days following closing, and the closing itself depends on actual share delivery and listing approval.
Bottom line: This modestly improves the form and potential liquidity of PharmaCyte’s Q/C investment while extending the counterparty’s runway. It is a small balance-sheet positive, not a change to the company’s stalled clinical story.
Closing upon Nasdaq approval and actual share delivery
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!